<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683628</url>
  </required_header>
  <id_info>
    <org_study_id>SI016033012</org_study_id>
    <nct_id>NCT03683628</nct_id>
  </id_info>
  <brief_title>Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC</brief_title>
  <official_title>Treatment of Intermittent Claudication by G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of
      patients with PAD who presented with intermittent claudication. Forty PAD patients who
      presented with intermittent claudication will be randomized into 2 groups. The control group
      will be treated by medication and walking exercise 3 times/ week. The experiment group will
      be injected G-CSF mobilized mononuclear cell ,medication and walking exercise 3 times/ week.
      Ankle brachial index(ABI), Toe brachial index (TBI) and transcutaneous oxygen measurement
      will be evaluated at the day of randomization, 1 , 3, 6 and 12 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of
      patients with PAD who presented with intermittent claudication. Forty PAD patients who
      presented with intermittent claudication will be randomized into 2 groups. The control group
      will be treated by medication and walking exercise 3 times/ week. The experiment group will
      be injected G-CSF mobilized mononuclear cell ,medication and walking exercise 3 times/ week.
      Ankle brachial index(ABI), Toe brachial index (TBI) and transcutaneous oxygen measurement
      will be evaluated at the day of randomization, 1 , 3, 6 and 12 months in the control group
      and day of randomization, 1 , 3, 6 and 12 months after injection of PB-MNC in the experiment
      group. Pain free walking distance will be evaluated at the day of randomization, 1 , 3, 6 and
      12 months by pedometer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The assessor who measure the pain free walking distance, ABI, TBI,TCOM do not know the result of randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain free walking distance</measure>
    <time_frame>3 month</time_frame>
    <description>the maximum distance which patient could walk without pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial index (ABI)</measure>
    <time_frame>1,3,6,12 month</time_frame>
    <description>Ankle brachial indexThe Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm. It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toe brachial index (TBI)</measure>
    <time_frame>1,3,6,12 month</time_frame>
    <description>Toe brachial indexThe toe brachial index is the ratio between toe pressure and the highest of the two brachial pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous oxygen measurement (TCOM)</measure>
    <time_frame>1,3,6,12 month</time_frame>
    <description>Transcutaneous oxygen measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Health Survey (SF36)</measure>
    <time_frame>1,3,6,12 month</time_frame>
    <description>SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain free walking distance</measure>
    <time_frame>1,6,12 month</time_frame>
    <description>the maximum distance which patient could walk without pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Intermittent Claudication</condition>
  <condition>PAD</condition>
  <condition>Atherosclerotic Ischemic Disease</condition>
  <arm_group>
    <arm_group_label>PB-MNC therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb, Aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No PB-MNC therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PB-MNC therapy</intervention_name>
    <description>The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week</description>
    <arm_group_label>PB-MNC therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No PB-MNC therapy</intervention_name>
    <description>Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week</description>
    <arm_group_label>No PB-MNC therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic arterial occlusive disease who presented with intermittent
             claudication

        Exclusion Criteria:

          -  Recent myocardial infarction

          -  Severe valvular heart disease

          -  After organ transplantation

          -  Cardiomyopthy( EF&lt; 25%)

          -  Liver failure

          -  Coagulopathy

          -  HIV

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuttawut SERMSATHANASAWADI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuttawut Sermsathanasawadi, MD, PhD</last_name>
    <phone>+6624198021</phone>
    <email>nuttawut@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuttawut SERMSATHANASAWADI</last_name>
      <phone>+6624198021</phone>
      <email>nuttawut@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>December 25, 2018</last_update_submitted>
  <last_update_submitted_qc>December 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

